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Introduction {#sec001}
============

Malignant cell identification and characterization in pleural effusions are essential for the diagnosis and management of patients affected by primary or metastatic cancer. In this context, the identification of new biomarkers is required to improve the differential diagnosis between cancer subtypes, to choose the most appropriate therapy, and to make prognostic correlations.

Nuclear abnormalities, such as aberrant shape, irregular chromatin texture, and prominent nucleoli, are hallmarks of carcinoma cells \[[@pone.0183136.ref001],[@pone.0183136.ref002]\] and are commonly used to diagnose malignancies \[[@pone.0183136.ref002],[@pone.0183136.ref003]\]. The nuclear matrix is thought to be a principal determinant of nuclear architecture, particularly through its interactions with the nuclear envelope \[[@pone.0183136.ref004]--[@pone.0183136.ref006]\]. Nuclear matrix results from chemical preparation, using high salt saline solution, and is composed of the peripheral nuclear *lamina*, an internal network of proteins and residual nucleolus. Nuclear matrix includes nucleoskeleton, mostly composed of lamin filament networks, and other proteins, such as ribonucleoproteins, nuclear mitotic apparatus (NuMA)... \[[@pone.0183136.ref007],[@pone.0183136.ref008]\]

The nuclear *lamina* is a network of lamin filaments interacting with lamin-associated proteins and is located underneath the inner nuclear envelope. In both the nuclear *lamina* and matrix, lamins act as scaffolding proteins that are involved in numerous nuclear functions, such as chromatin organization, DNA repair, DNA replication, transcription, and epigenetic regulation, with regulatory effects on the cell cycle and differentiation, apoptosis, and senescence \[[@pone.0183136.ref009],[@pone.0183136.ref010]\].

The type V intermediate filament lamins are the principal components of the nuclear matrix, including the nuclear *lamina*. Lamins predominate in the nuclear *lamina* and are more diffuse throughout the nucleoplasm, at significantly lower concentrations than in the nuclear *lamina* \[[@pone.0183136.ref003],[@pone.0183136.ref008],[@pone.0183136.ref011]\]. Lamins are divided into A-type and B-type, which are encoded by three genes, *LMNA*, *LMNB1*, and *LMNB2*. The alternative splicing of *LMNA*, located at chromosome 1q21.1--21.3, produces two major A-type lamins, lamin A and lamin C, which are expressed in most differentiated cells, and two minor isoforms, lamin AΔ10, which is expressed in some carcinoma cell lines \[[@pone.0183136.ref012]\], and lamin C2, which is specifically expressed in germ cells. B-type lamins are encoded by two distinct genes, *LMNB1*, located at chromosome 5q23, and *LMNB2*, located at chromosome 19p13 \[[@pone.0183136.ref004],[@pone.0183136.ref012]--[@pone.0183136.ref015]\]. Lamins B1 and B2 show ubiquitous expression, whereas lamin B3, produced from *LMNB2* by alternative splicing, is specifically expressed in germ cells \[[@pone.0183136.ref004],[@pone.0183136.ref009]\].

Lamins A, B1, and B2 are first expressed as cytosolic precursors called prelamins that undergo numerous post-translational processing steps involving their carboxy terminal CaaX box. First, a farnesyltransferase adds a farnesyl group to the cysteine. This 15-carbon hydrophobic group temporarily (prelamin A) or permanently (prelamin B; mature B-type lamins) anchors the prelamins to the cytosolic leaflet of the endoplasmic reticulum membrane or of the outer nuclear envelope. During the next step, FACE1/ZMPSTE24 or FACE2/Rce1 protease removes the last three amino acids, aaX. Then, the farnesylated cysteine is methylated by an isoprenylcysteine carboxymethyl transferase (ICMT). After this last step of their processing, mature B-type lamins remain farnesylated and carboxymethylated, are imported into the nucleoplasm, and are located in the nuclear *lamina*, anchored to the inner nuclear envelope. Unlike B-type prelamins, prelamin A undergoes another proteolytic cleavage specifically performed by FACE1/ZMPSTE24, which clips off the last 15 residues, including the farnesylated and carboxymethylated cysteine. This removal leads to a mature soluble lamin A, which is imported into the nucleoplasm and is localized in both the nuclear *lamina* and the rest of the nuclear matrix \[[@pone.0183136.ref003],[@pone.0183136.ref004],[@pone.0183136.ref014],[@pone.0183136.ref016]\]. Lamin C, lacking the CaaX prenylation box, is directly synthesized as a mature form and shares the same nuclear location as lamin A \[[@pone.0183136.ref004],[@pone.0183136.ref014],[@pone.0183136.ref016]\]. Mutations in *LMNA* or defects in prelamin A posttranslational processing cause a wide range of diseases called laminopathies \[[@pone.0183136.ref003],[@pone.0183136.ref004],[@pone.0183136.ref016]\].

Previous studies have suggested that lamins are involved in tumor development and progression \[[@pone.0183136.ref017]\]. Variations in lamin localization and/or expression levels have been reported in several cancer subtypes \[[@pone.0183136.ref018],[@pone.0183136.ref019]\]. The heterogeneous expression of lamin A/C has been described \[[@pone.0183136.ref003],[@pone.0183136.ref014]\], primarily using western blots and immunohistochemical staining, in cancer cells obtained from colorectal \[[@pone.0183136.ref006],[@pone.0183136.ref020]--[@pone.0183136.ref022]\], gut \[[@pone.0183136.ref023]\], gastric \[[@pone.0183136.ref006]\], lung \[[@pone.0183136.ref018],[@pone.0183136.ref019]\], breast \[[@pone.0183136.ref001],[@pone.0183136.ref024]\], prostate \[[@pone.0183136.ref009],[@pone.0183136.ref025],[@pone.0183136.ref026]\], testis \[[@pone.0183136.ref027]\], skin \[[@pone.0183136.ref028],[@pone.0183136.ref029]\] hematologic \[[@pone.0183136.ref010]\], cervical \[[@pone.0183136.ref030]\], endometrial \[[@pone.0183136.ref031]\] and ovarian \[[@pone.0183136.ref032],[@pone.0183136.ref033]\] tumors. Opposite results have been reported concerning the prognosis associated with a reduced or lack of expression of lamin A/C in gastric and advanced colon carcinomas \[[@pone.0183136.ref006],[@pone.0183136.ref021]--[@pone.0183136.ref023]\]. In lung cancer, only a few older studies in cell lines or human tissues have shown reduced lamin A/C expression in small cell lung cancer (SCLC) in contrast with non-SCLC \[[@pone.0183136.ref017]--[@pone.0183136.ref019]\]. A few publications have described decreased expression of B-type lamins in gastric and colon carcinomas \[[@pone.0183136.ref023]\] and in some lung adenocarcinomas \[[@pone.0183136.ref018]\], whereas the reverse was observed in prostate carcinoma \[[@pone.0183136.ref025],[@pone.0183136.ref026]\].

In addition to these quantitative abnormalities, the aberrant cytoplasmic localization of A- and B-type lamins has also been observed in some colon, gastric, and pancreatic cancer and in non-SCLC cells \[[@pone.0183136.ref017],[@pone.0183136.ref023]\].

Altogether, these studies propose lamin expression as a biomarker for cancer diagnosis, prognosis, and/or follow-up \[[@pone.0183136.ref014]\]. However, previous studies have only analyzed human cancer cell lines and lung cancer tissues from biopsies.

The aim of the present study was to investigate lamins A, C, and B1 as potential biomarkers in cancer cells from metastatic pleural effusions.

Materials and methods {#sec002}
=====================

Study design {#sec003}
------------

This study was an observational study with no intervention. Patients were recruited in the Thoracic Oncology, Pleural Disease, and Interventional Pulmonology Department at Marseille North Hospital. The study was registered on the ClinicalTrials.gov web site (identifier: NCT01284777). The protocol was approved by the Marseille Ethical Committee (Comité de Protection des Personnes Sud Méditerranée I--References number: 2010-A00295-34) and performed in accordance with the Declaration of Helsinki. Subjects provided informed written consent before participation.

Cytological analysis {#sec004}
--------------------

Pleural effusions were received in the Cell Biology Laboratory at La Timone Hospital of Marseille for conventional cytological diagnosis. Briefly, a fraction of the fresh sample was cytospun (Thermo Electron Corporation, Cheshire, United Kingdom) at 450 g for 3 minutes, and another portion was smeared from the sediment after centrifugation (Jouan, Saint-Herblain, France) at 600 g for 5 minutes.

The slides were air-dried or fixed in acetone and methanol and then stained with May-Grunwald-Giemsa (MGG) or Papanicolaou stains, respectively. The remaining fraction of the sample was used to prepare slides and cell pellets and was stored at -70°C until use.

Using a light microscope (Leica, Wetzlar, Germany), malignant cells were manually counted, and conventional cytological analysis was completed by immunocytochemical phenotyping. Histological confirmation was achieved in most cases (90%) by conventional analysis and immunohistochemistry on paraffin sections. For the other patients, biopsy and pathological examination could not be performed. Therefore, histologic subtype and primitive tumor localization were defined based on the cytology only associated with the physical examination and radiological imaging according to international recommendations \[[@pone.0183136.ref034]\].

Primary antibodies used for immunofluorescence (IF) and/or western blotting (WB) {#sec005}
--------------------------------------------------------------------------------

The following primary antibodies were used for immunofluorescence (IF) and/or western blotting (WB): mouse anti-lamin A \[ab8980, Abcam, Paris, France (IF: 1/100, WB: 1/200)\]; rabbit anti-lamin C \[BP4505, Acris, Herford, Germany (IF: 1/100, WB: 1/230)\]; mouse anti-lamin A/C \[MAB3211, Merck Millipore, Massachusetts, United States (WB: 1/200)\]; goat anti-lamin A/C \[sc6215, Santa Cruz, Texas, United States (WB: 1/200)\]; rabbit anti-lamin A/C \[sc20681, Santa Cruz (WB: 1/200)\]; rabbit anti-lamin B1 \[ab16048, Abcam (WB: 1/250)\]; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) \[MAB374, Merck Millipore (WB: 1/40,000)\].

For IF, the following isotype antibodies were used as negative controls: mouse IgG (015-000-003, Jackson ImmunoResearch, Suffolk, UK); and rabbit IgG (AB-105-C, R&D, Minnesota, United States).

Dermal fibroblast culture and total protein extraction {#sec006}
------------------------------------------------------

The culture and storage of control dermal fibroblasts were performed by the Biological Resource Center of the Department of Medical Genetics (Marseille Timone Hospital).

Cells were cultured in DMEM (Life Technologies) containing 20% FBS (Life Technologies), 2 mM L-glutamine (Life Technologies), and 2X penicillin-streptomycin (Life Technologies) at 37°C in a humidified atmosphere containing 5% CO~2~. Total fibroblast proteins were extracted (1% Triton X100, 0.1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl pH 7.5, 1X Complete EDTA-free protease inhibitor cocktail, 1 mM Na~3~VO~4~, 1 mM PMSF). Cells were sonicated twice (30 seconds each), incubated at 4°C for 30 minutes, and then centrifuged at 10,000 g for 10 minutes. Protein concentrations were determined with the BCA™ Protein Assay (Thermo Scientific) according to the manufacturer's instructions \[[@pone.0183136.ref035]\]. Dermal fibroblasts were used as controls in western blot experiments.

Nuclear protein extraction from pleural effusion cells {#sec007}
------------------------------------------------------

Nuclear proteins were extracted from frozen cell pellets \[[@pone.0183136.ref036]\]. Briefly, cells were incubated during centrifugation (10 min, 800 g, 4°C) in lysis buffer \#1 (10 mM Tris HCl pH 7.5, 30 mM NaCl, 3 mM MgCl~2~, 1 mM PMSF, 0.5 μg/ml aprotinin, 0.5% NP40, and 1X Complete EDTA-free protease inhibitor cocktail (Roche, Meylan, France)).

The supernatant was then removed, and the pellet was washed and incubated for 1 h at 4°C in lysis buffer \#2 (50 mM Tris HCl pH 7.5, 250 mM sucrose, 5 mM MgSO~4~, 1 mM PMSF, 0.5 μg/ml aprotinin, 0.5% NP40, 500 kU/ml DNase (D-5025, Sigma), 25 kU/ml RNase (D-5503, Sigma), and 1X Complete EDTA-free protease inhibitor cocktail). After centrifugation (800 g, 15 minutes, 4°C), the supernatant was removed, and the pellet was dissolved in 1.6 M NaCl. Protein concentrations were determined using the BCA™ Protein Assay (Thermo Scientific, Courtaboeuf, France) according to the manufacturer's instructions.

Western blotting and lamin quantification {#sec008}
-----------------------------------------

Proteins were extracted and analyzed by a standard western blotting procedure, described as follows.

Protein lysates were separated on Criterion™ XT 7% Tris-Acetate precast gels (345--0135, Bio-Rad, California, United States) and transferred to Immobilon-FL PVDF membranes (Merck-Millipore). Membranes were blocked for one hour in 1:2 blocking buffer for near-infrared fluorescent western blotting (Rockland, Pennsylvania, United States). The blocked membranes were incubated with primary antibodies for one hour at RT and then washed and incubated with IR-Dye-conjugated secondary antibodies for one hour at RT. Bound antibodies were detected and analyzed on an Odyssey^®^ V3.0 imaging system (LI-COR Biosciences, Homburg, Germany) according to the manufacturer's instructions.

Secondary antibodies conjugated with IR-Dye 800 or 680 were used according to the manufacturer's instructions (926--32212, 926--32214, 926--32223, 926--32224, 1/5000, LI-COR^®^ Biosciences) \[[@pone.0183136.ref037]\].

The quantities of lamin A, C, and B1 proteins were measured by fluorescence at infrared wavelengths. Lamin A expression was normalized to the total amount of lamins A and C, and a ratio was established \[Lamin A / (Lamin A + Lamin C)\].

Immunofluorescence microscopy {#sec009}
-----------------------------

Cells were centrifuged (450 g, 5 minutes) in a Cytospin (Thermo Electron Corporation), and slides were stored at -70°C prior to use. Cells were immunostained using a previously described protocol (37). Briefly, after 15 minutes of fixation at room temperature (RT) in a 4% paraformaldehyde + 2% sucrose solution, cells were permeabilized using a permeabilization buffer (0.5% Triton X-100, 50 mM NaCl, 300 mM sucrose, 20 mM HEPES pH 7.5, 3 mM MgCl~2~) for 3 minutes at RT. The cells were then incubated with the primary antibodies for 40 minutes at 37°C. After washing, the cells were incubated with secondary antibodies (A11001, A11055, A11012; Life Technologies, Saint-Aubin, France; 1/400) for 20 minutes at 37°C. The nuclei were counterstained with DAPI (0.1 **μ**g/mL, Sigma, Lyon, France) for 10 minutes at RT. The slides were mounted using FluorSave™ reagent (Merck Millipore) and were observed on a fluorescence microscope (ApoTome.2 Zeiss).

Flow cytometry {#sec010}
--------------

A flow cytometry analysis was performed on adenocarcinoma cells from seven patients, on the remaining available samples.

Cells were stored in medium containing 90% FBS and 10% DMSO at -70°C until use. Red blood cells were lysed before storage using NH~4~Cl lysis buffer. Cells were fixed at RT in 4% paraformaldehyde solution and washed in PBS containing 0.2 M glycine prior to permeabilization at RT using the homemade permeabilization buffer detailed in the immunofluorescence method. Cells were then incubated in PBS containing 2% BSA for 20 minutes and for one hour with the following antibodies: anti-CD45-PECy7 (MHCD4512; Life Technologies), anti-EMA-PE (355604; Biolegend, California, United States), and anti-lamin A-AF647 (Ab8980; Abcam); the anti-lamin A antibody was labeled with the APEX antibody labeling kit Alexa 647 (A10475; Life Technologies). The LIVE/DEAD^®^ Fixable Near-IR Dead Cell Stain Kit (L10119, Life Technologies) was used to determine the viability of cells.

Lamin A and EMA (epithelial membrane antigen, also known as MUC-1) protein expression was analyzed in malignant cells by flow cytometry (Attune^®^, Life Technologies). The percentage of positive cells, median fluorescence intensity, and standard deviation (MFI ± SD) were measured in an average of 14,000 live, CD45-negative cells that were considered carcinoma cells. Anti-IgG1k-PE (400114, Biolegend), anti-IgG1-PeCy7 (MG112, Life Technologies), and anti-IgG3-AF647 (560803, BD Pharmingen, Le Pont de Claix, France) were used as isotype controls.

Statistical analyses {#sec011}
--------------------

The statistical analysis was performed with the Prism software (GraphPad Software Inc., California, United States). Significant differences were determined using t-test or Mann-Whitney test; Chi-square or Fisher tests were conducted to evaluate the differences between groups for qualitative variables; and correlations were established using Pearson or Spearman tests, depending on the Gaussian distribution of the values.

All statistical results were 2-sided and a *P-*value \< 0.05 was considered significant.

Results {#sec012}
=======

Participant characteristics {#sec013}
---------------------------

Patients diagnosed with a metastatic pleural effusion from lung adenocarcinoma in our institution were prospectively recruited. 32 patients were enrolled because their pleural effusion contained at least 20% adenocarcinoma cells.

Patient demographics and clinical and cytological data were prospectively collected, at the time of the pleural puncture ([Table 1](#pone.0183136.t001){ref-type="table"}). The cohort included 14 females and 18 males, with a median age of 69 years (range 50--96 years).

10.1371/journal.pone.0183136.t001

###### Pathological and clinical characteristics of patients, according lamin A expression.

![](pone.0183136.t001){#pone.0183136.t001g}

  -------------------------------------------------------------------------------------------------
  Clinicopathological variables\                         Low (n = 12)   High (n = 20)   p-value
  Number of patients (%)                                                                
  ------------------------------------------------------ -------------- --------------- -----------
  **Gender**                                                                            1

  \- Male                                                7 (58%)        11 (55%)        

  \- Female                                              5 (42%)        9 (45%)         

  **Age, years (median)**                                66 (50;96)     69 (50;90)      0.95

  **Smoking history**                                    8 (67%)        16 (80%)        0.4

  **Professional exposure**                              3 (25%)        3 (15%)         0.65

  **Mutation**                                                                          0.68

  \- *EGFR*                                              2 (17%)        4 (20%)         

  \- *KRAS*                                              2 (17%)        3 (15%)         

  \- *BRAF*                                              1 (8%)         0               

  \- *ALK* or *ROS1* rearranged                          0              1 (5%)          

  \- Wild type or unknown                                7 (58%)        12 (60%)        

  **WHO Performance Status** (median)\                   2              1               **0.007**
  Patients repartition:                                                                 

  \- 0                                                   1 (8%)         10 (50%)        **0.037**

  \- 1                                                   3 (25%)        5 (25%)         

  \- 2                                                   6 (50%)        5 (25%)         

  \- 3                                                   2 (17%)        0               

  \- 4                                                   0              0               

  **Association of bone, lung and pleural metastasis**   9 (75%)        5 (25%)         **0.01**
  -------------------------------------------------------------------------------------------------

Reduced expression of lamin A but not of lamin C was observed in a sub-group of lung adenocarcinomas {#sec014}
----------------------------------------------------------------------------------------------------

Lamin A, B1, and C bands were observed by western blot at the expected sizes (72 kDa, 68 kDa, and 65 kDa, respectively).

A strong reduction in lamin A but not in lamin C expression was specifically observed in 12 (37.5%) patients with lung adenocarcinoma pleural metastasis using a mouse anti-lamin A/C antibody (Jol2) (Panel A in [Fig 1](#pone.0183136.g001){ref-type="fig"} and [S1 Fig](#pone.0183136.s001){ref-type="supplementary-material"}). This result was confirmed by using two others anti-lamin A/C antibodies from goat or rabbit, as well as anti-lamin A and anti-lamin C specific antibodies (Panel A in [S2 Fig](#pone.0183136.s002){ref-type="supplementary-material"}). Moreover, same results were obtained using total proteins extraction (Panel B in [S2 Fig](#pone.0183136.s002){ref-type="supplementary-material"}).

![Expression pattern of lamins in lung adenocarcinoma cells from metastatic pleural effusions.\
(A) Representative results of western blot analysis of nuclear extracts from patients (Pt) 5, 9, 10, 11, and 16 and from total proteins extracts of control dermal fibroblasts using a mouse anti-lamin A/C antibody (Jol2). (B) Analyses of lamin A levels quantified after normalization with the total amount of lamins A and C showed two lamin A expression groups (p\<0.001; Mann--Whitney test).](pone.0183136.g001){#pone.0183136.g001}

The lamin ratio \[r = A / (A + C)\] distinguished two groups of lung adenocarcinoma patients; 37.5% (12/32) of patients are in the low lamin A expression group with a ratio significantly reduced (p\<0.001, Mann-Whitney test), exhibiting an eightfold decrease (r = 0.05 ± 0.03) compared to the patients in the high lamin A expression group (r = 0.39 ± 0.15) (Panel B in [Fig 1](#pone.0183136.g001){ref-type="fig"}).

In accordance with Western blot analysis, immunofluorescence experiments showed, in cancer cells, a variable expression of lamin A depending on patient group (low or high lamin A expression group), whereas positive nuclear staining with anti-lamin C antibody was consistently observed. As shown in [Fig 2](#pone.0183136.g002){ref-type="fig"}, most adenocarcinoma cells from patients from high lamin A expression group were intensively positive for lamin A antibody staining (ex: Pt51), whereas a high part of adenocarcinoma cells from patients from low lamin A expression group showed a weak staining (ex: Pt58).

![Immunofluorescence staining of lamins A and C in cells from metastatic pleural effusions.\
Cells from metastatic pleural effusions of lung adenocarcinoma from high (Patient (Pt) 51) and low (Pt 58) lamin A expression group were stained with lamin A and lamin C antibodies. DAPI: counterstained nuclei. White stars: dyskaryotic nuclei of cancer cells. Orange arrows: cancer cells with a high lamin A expression. White arrows: cancer cells with a low lamin A expression. Asterisk: normal leukocytes.](pone.0183136.g002){#pone.0183136.g002}

In normal leukocytes, lamin A/C expression was very weak or absent. Cytological analysis showed that cancer cells exhibited nuclear morphological abnormalities, such as dyskaryosis, blebs, and micronuclei. No aberrant cytoplasmic localization of lamin A/C was observed ([Fig 2](#pone.0183136.g002){ref-type="fig"}).

Reduced lamin A expression was correlated with the loss of EMA/MUC-1 in adenocarcinoma cells {#sec015}
--------------------------------------------------------------------------------------------

Flow cytometry analysis was performed on adenocarcinoma cells from five patients in the high lamin A expression group (patients 16, 21, 34, 37 and 38) and two patients in the low lamin A expression group (patients 20 and 45). Dead cells and leukocytes were excluded from the analysis by positive staining with the LIVE/DEAD^®^ viability marker and CD45, respectively. CD45-negative cells were considered adenocarcinoma cells (Panels A and B in [Fig 3](#pone.0183136.g003){ref-type="fig"}), as normal mesothelial cells accounted for less than 2% of these pleural effusions. Lamin A and EMA (epithelial membrane antigen, also known as MUC-1) protein expression was then specifically studied in these adenocarcinoma cells (Panels C and D in [Fig 3](#pone.0183136.g003){ref-type="fig"}). Three main adenocarcinoma cell populations were defined: cells expressing both lamin A and EMA (LamA+/EMA+); cells lacking both lamin A and EMA (LamA-/EMA-); and cells expressing lamin A associated with the loss of EMA (LamA+/EMA-). The percentages of these three main cell populations differed between patients (Panel D in [Fig 3](#pone.0183136.g003){ref-type="fig"} and [Table 2](#pone.0183136.t002){ref-type="table"}). A fourth minor cell population expressing EMA but lacking lamin A (LamA-/EMA+) was considered negligible because it represented less than 4% of cells.

![Flow cytometry analysis of lamin A and EMA in adenocarcinoma cells.\
(A to E) Representative results of lamin A expression in malignant cells contained in 2 metastatic pleural effusions from lung adenocarcinoma (left panel = Patient (Pt) 16 and right panel = Pt 45) using flow cytometry. Positivity thresholds were defined using isotype controls. **Cell analysis strategy:** (A) Cells were selected using SSC and FSC criteria. (B) Live cells lacking CD45 expression were considered adenocarcinoma cells (CD45-/EMA- and CD45-/EMA+ cells). Leukocytes (CD45+/EMA- cells) were excluded from analysis. (C and D) **Lamin A and EMA expression in adenocarcinoma cells.** See also [Table 2](#pone.0183136.t002){ref-type="table"}.(E) **Correlation of EMA and lamin A expression in adenocarcinoma cells:** The percentage of lamin A-expressing adenocarcinoma cells was positively correlated with the percentage of EMA-expressing cells (p = 0.0123; Spearman test).](pone.0183136.g003){#pone.0183136.g003}

10.1371/journal.pone.0183136.t002

###### Lamin A and EMA expression in adenocarcinoma cells.

![](pone.0183136.t002){#pone.0183136.t002g}

  ---------------------------------------------------------------------
  Patient                             Pt16   Pt45             
  ----------------------------------- ------ --------- ------ ---------
  **Lamin A- cells**                  18.7   8,068     54.8   6,202

  **Lamin A+ cells**                  79.3   352,369   39.7   574,321

  **EMA- cells**\                     27.2   24,210    75.6   21,542
  (EMA-/LamA- and EMA-/LamA+ cells)                           

  **EMA+ cells**\                     72.8   835,349   24.3   393,542
  (EMA+/LamA- and EMA+/LamA+ cells)                           
  ---------------------------------------------------------------------

LamA = lamin A; MFI = median fluorescence intensity.

All patients exhibited an adenocarcinoma cell population completely lacking lamin A, but the percentage of this cell population differed between patients, depending on patient group (low or high lamin A expression group) (Panels C and D in [Fig 3](#pone.0183136.g003){ref-type="fig"} and [Table 2](#pone.0183136.t002){ref-type="table"}). For example, as shown in [Table 2](#pone.0183136.t002){ref-type="table"}, 18.7% of adenocarcinoma cells from Patient 16 (Pt16, from high lamin A expression group) were negative for lamin A staining whereas 54.8% of adenocarcinoma cells from Patient 45 (Pt45, from low lamin A expression group) lacked lamin A expression. Thus, these results illustrate that in patients from low lamin A expression group (ex: Pt45), adenocarcinoma cell population completely lacking lamin A is predominant compared to patients from high lamin A expression group (ex: Pt16) (18.7% and 54.8%, respectively).

Moreover, the expression marker for carcinoma cell differentiation, EMA, was also lacking in some adenocarcinoma cells (Panel D in [Fig 3](#pone.0183136.g003){ref-type="fig"}), and interestingly, the percentage of lamin A+ adenocarcinoma cells was positively correlated with the percentage of EMA+ cells (p = 0.0123) (Panel E in [Fig 3](#pone.0183136.g003){ref-type="fig"}).

These flow cytometry experiments identified a sub-population of metastatic lung adenocarcinoma cells lacking lamin A expression, and we showed that this decrease in lamin A expression was correlated with the loss of EMA/MUC-1.

Lamin A expression in lung adenocarcinoma cells was inversely correlated with the number of metastatic sites and the WHO Performance status {#sec016}
-------------------------------------------------------------------------------------------------------------------------------------------

Clinical data from the 32 patients with lung adenocarcinoma were collected at the time of the pleural puncture and analyzed according to their high or low lamin A expression status ([Table 1](#pone.0183136.t001){ref-type="table"}).

Interestingly, the number of total metastatic sites was inversely correlated with the lamin ratio \[A / (A + C)\], reflecting lamin A expression (p = 0.04; Pearson test) (Panel A in [Fig 4](#pone.0183136.g004){ref-type="fig"}). The association of bone, lung and pleural metastasis was more frequently observed in patients of the low lamin A expression group (9/12; 75%) compared with the patients belonging to the high lamin A expression group (5/20; 25%) (p = 0.01; Fisher test).

![Correlation between Lamin A expression in metastatic lung adenocarcinoma cells and number of metastatic sites and WHO Performance status.\
(A) The number of metastasis sites was inversely correlated with lamin A expression (p = 0.04; Pearson test). (B) The patients repartition was statistically different according the lamin A expression group (p = 0.037; Chi-square test). PS = Performance status. (C) The WHO Performance status was inversely correlated with lamin A expression (p = 0.01; Spearman test).](pone.0183136.g004){#pone.0183136.g004}

Moreover, patients from the low lamin A group exhibited a higher Performance status score than those from the high lamin A group (2 *vs* 1, respectively; *p* = 0.007, unpaired t-test) and the patients repartition was statistically different according the lamin A expression group (*p* = 0.037; Chi-square test) (Panel B in [Fig 4](#pone.0183136.g004){ref-type="fig"}). In addition, the Performance status score was inversely correlated with the lamin ratio \[A / (A + C)\] (*p* = 0.01; Spearman test) (Panel C in [Fig 4](#pone.0183136.g004){ref-type="fig"}).

Discussion {#sec017}
==========

We combined immunofluorescence, western blotting, and flow cytometry for the first time to study lamins in cancer cells from metastatic pleural effusions. Previous studies have already described lamin expression abnormalities in cancer cells but have been restricted to cancerous lung tissues from primitive tumor biopsies and have relied primarily on immunohistochemical methods \[[@pone.0183136.ref017]--[@pone.0183136.ref019]\].

Interestingly, we reported reduced expression of lamin A but not of lamin C in a sub-group of metastatic lung adenocarcinoma patients. No variations in lamin B1 expression were observed in these cells.

Lamins A and C, which are encoded by the same *LMNA* gene, both result from alternative splicing in exon 10, which produces two different mRNAs that encode prelamin A (the precursor of lamin A) and lamin C \[[@pone.0183136.ref004]\]. Therefore, we hypothesize that the loss of lamin A but not lamin C expression in pleural metastatic adenocarcinoma cells could result from regulation by miRNAs or splicing factors.

Recent publications reported that miR-9 negatively controls lamin A but not lamin C expression due to the specific targeting of lamin A mRNA in neural cells \[[@pone.0183136.ref038],[@pone.0183136.ref039]\]. It would be thus very interesting to investigate miR-9 expression using RT-qPCR assays in metastatic pleural effusions from lung adenocarcinoma in the two lamin A expression groups. As these samples contained cancer cells mixed with miR-9 expressing leukocytes, it would be useful to correlate the level of miR-9 with lamin expression specifically in metastatic cells after their isolation by FACS selection or using magnetic beads.

The splicing factors involved in the alternative production of lamins A and C are still unknown. The serine-arginine (SR)-rich splicing factor 1 (SRSF1) controls *LMNA* pre-mRNA alternative splicing \[[@pone.0183136.ref040]\], leading to the production of progerin (the truncated prelamin A protein produced in HGPS (Hutchinson-Gilford Progeria Syndrome) cells and during physiological aging) \[[@pone.0183136.ref004],[@pone.0183136.ref041]\]. SRSF1 has been proposed as a proto-oncogene because it is overexpressed in many cancers \[[@pone.0183136.ref042]\]. In particular, in lung adenocarcinoma, SRSF1 overexpression is associated with a more aggressive phenotype, the presence of metastases, and chemotherapy resistance \[[@pone.0183136.ref043]\]. Progerin was found to be expressed in many human cancer cell lines, and its ectopic expression in a prostate cancer cell line led to enhanced growth and stronger tumorigenic potential *in vivo* after subcutaneous injection into nude mice \[[@pone.0183136.ref044]\].

Our flow cytometry analyses identified a sub-population of metastatic lung adenocarcinoma cells lacking lamin A expression, and we showed that this decrease in lamin A expression was correlated with the loss of EMA/MUC-1.

The epithelial to mesenchymal transition (EMT) is characterized by the downregulation of epithelial differentiation markers, such as EMA, and is associated with the upregulation of mesenchymal markers \[[@pone.0183136.ref045],[@pone.0183136.ref046]\]. EMT increases cell motility and invasiveness and is correlated with invasive tumor metastasis and poor prognosis \[[@pone.0183136.ref043],[@pone.0183136.ref046]--[@pone.0183136.ref048]\]. Nevertheless, several publications have described EMA as an EMT inducer due to glycosylation and overexpression in carcinomas \[[@pone.0183136.ref047],[@pone.0183136.ref048]\]. In future studies, it would be useful to compare both lung adenocarcinoma metastatic cells and primary tumors to analyze EMA and lamin A expression, together with other EMT markers that are already known to evolve during tumor progression or metastasis.

Some studies have reported SRSF1 and miR-9 involvement in EMT during lung cancer \[[@pone.0183136.ref043],[@pone.0183136.ref049]\]. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long, non-coding nuclear RNA, is known as a poor prognostic marker and a predictive marker for metastasis development in lung cancer; it targets genes involved in cell migration, tumor growth and the EMT \[[@pone.0183136.ref050]--[@pone.0183136.ref053]\]. Interestingly, miR-9 negatively regulates the expression of MALAT-1 \[[@pone.0183136.ref054]\], and MALAT-1 is implicated in the regulation of SRSF1 \[[@pone.0183136.ref050],[@pone.0183136.ref055],[@pone.0183136.ref056]\].

Therefore, it would be of interest to explore and concomitantly correlate miR-9, SRSF1 and MALAT-1 expression in lung adenocarcinoma metastatic cells and in primary tumors, and also to correlate their levels with EMT markers and lamin A expression. Furthermore, as MALAT-1 is detectable in peripheral human blood and has been proposed as a blood biomarker of NSCLC \[[@pone.0183136.ref057]\], we could investigate this new parameter in a prospective cohort.

Moreover, our work showed that the lamin ratio, reflecting lamin A expression, was inversely correlated with the number of total metastatic sites, with a frequent association of lung, pleural and bone metastasis in patients with low lamin A expression. Our data are consistent with a recent publication that described a reduction of lamin A but not of lamin C expression in primitive epithelial ovarian cancer tissues associated with metastasis potential and poor prognosis \[[@pone.0183136.ref032]\]. Similarly, in prostate carcinoma cells, reduced amounts of lamin A were correlated to an increased risk for lymph node metastasis \[[@pone.0183136.ref026]\]. Furthermore, the number of metastatic sites has already been linked to overall survival in lung adenocarcinoma \[[@pone.0183136.ref058],[@pone.0183136.ref059]\]. Interestingly Lee et *al*., also demonstrated that bone is one of the most frequent metastasis localization in lung adenocarcinoma \[[@pone.0183136.ref058],[@pone.0183136.ref059]\] whereas the presence of bone metastases is considered as an adverse prognostic factor associated with shorter survival \[[@pone.0183136.ref060]\].

Furthermore, miR-9 seems to be involved in tumorigenesis and cancer progression. It can act as an oncogene or a tumor suppressor; several publications described various miR-9 expression patterns between cancerous and adjacent normal tissues or depending on the tumor type \[[@pone.0183136.ref049],[@pone.0183136.ref061]--[@pone.0183136.ref063]\]. Few publications have suggested that miR-9 promotes the metastasis of non-small cell lung cancer (NSCLC), and its up-regulation has been associated with poor prognosis \[[@pone.0183136.ref062],[@pone.0183136.ref063]\].

However, epigenetic miR-9 silencing was described as a poor prognosis in NSCLC primary tumors, especially in squamous cell carcinoma, and as a predictive marker of lymph node metastasis by cancer cell lines derived from other tumor types \[[@pone.0183136.ref061],[@pone.0183136.ref062]\].

Finally, our work showed that the reduction of lamin A expression was correlated with a poor WHO Performance status, which is considered as a gold standard prognostic measure \[[@pone.0183136.ref064]\]. It is proposed as the most established factor for assessing prognosis and is advised in guidelines for lung cancer treatment \[[@pone.0183136.ref064],[@pone.0183136.ref065]\]. Indeed, the Performance status represents a major criteria for treatment decision in advanced lung cancer as patients with a poor Performance status are expected to be unfit for conventional treatments \[[@pone.0183136.ref064]--[@pone.0183136.ref066]\].

Furthermore, the Performance status has been closely linked to overall survival in advanced lung adenocarcinoma, as a poor Performance status was associated with a reduced survival \[[@pone.0183136.ref058],[@pone.0183136.ref059],[@pone.0183136.ref064]\].

These publications emphasize here the probable link of a low lamin A expression with a poor prognosis and a shorter survival outcome, which need to be confirmed in a further study.

Conclusions {#sec018}
===========

In conclusion, our work, which is a pilot study, already showed significant results, suggesting that low lamin A but not lamin C expression in pleural metastatic cells could represent a major actor in the development of metastasis, associated with EMT and could account for a pejorative factor correlated with a poor Performance status.

These results should lead to better understand at the mechanistic level, the metastasis development in which nuclear matrix, and lamins in particular, could have a central role. Moreover, we intend to confirmed our results and to analyze EMT markers in a new prospective large study to emphasize the loss of lamin A as a poor prognostic marker and to understand the link between a lack of lamin A in lung adenocarcinoma cells and their metastatic potential.

Supporting information {#sec019}
======================

###### Expression patterns of lamins A and C in metastatic lung adenocarcinoma cells from pleural effusions observed by western blot analysis.

Representative results from various experiments using total protein extracts of dermal fibroblasts (control) and extracts of cells contained in metastatic pleural effusions from the 32 patients (Pt). Patients were separated according to the ratio A/(A+C). Patients with a ratio higher than 0.1 belonged to the "High lamin A expression group" whereas patients with a ratio under 0.1 were classified in the "Low lamin A expression group".

(TIF)

###### 

Click here for additional data file.

###### Confirmation of lamin A expression pattern in lung adenocarcinoma cells by western blot analysis, using different antibodies and total proteins extraction.

\(A\) Representative results of western blot analysis of nuclear extracts from patients (Pt) 5, 9, 10, 11, 16, 20 and 31 and from control dermal fibroblasts using a mouse anti-lamin A/C antibody (Jol2, MAB3211), a goat-anti-lamin A/C antibody (N18, sc6215), a rabbit-anti-lamin A/C antibody (H110, sc20681), anti-lamin A antibody (ab8980) and anti-lamin C antibody (BP4505).

\(B\) Representative results of western blot analysis of total protein extracts from patients (Pt) 20, 31, 45 (low lamin A group) and Pt 10, 11, 16, 21 and 27 (from high lamin A group) using a mouse anti-lamin A/C antibody (Jol2).

(TIF)

###### 

Click here for additional data file.
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